GlassScriptPhysician profile
Jagathi Devi Challagalla
NPI 1376521617
$76,246.21
in general payments reported to CMS, 2019-2025
65 companies · $6,729 in 2025
The $6,729 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,725 · 2020: $16K · 2021: $12K · 2022: $12K · 2023: $15K · 2024: $6,529 · 2025: $6,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $4,437 · Travel and Lodging: $2,479 · Honoraria: $2,345 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,680 · Education: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,674.25 |
| Food and Beverage | $4,436.91 |
| Travel and Lodging | $2,479.38 |
| Honoraria | $2,344.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,680.00 |
| Education | $582.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $7,985.34 | 2019-2025 | Tecvayli, Carvykti, Darzalex |
| Beigene USA, INC. | $6,487.50 | 2022-2023 | Brukinsa |
| Exelixis INC. | $6,357.45 | 2019-2025 | Cabometyx |
| Celgene Corporation | $6,129.20 | 2019-2025 | Reblozyl |
| Seagen INC. | $5,253.63 | 2019-2023 | Tukysa, Adcetris |
| Pfizer INC. | $5,196.59 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $3,920.45 | 2022-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $3,791.28 | 2019-2025 | Imfinzi, Calquence |
| Gilead Sciences, INC. | $3,564.45 | 2021-2025 | Trodelvy |
| Fresenius Kabi USA, LLC | $3,175.00 | 2021-2023 | Stimufend |
| Glaxosmithkline, LLC. | $2,520.65 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $1,841.68 | 2019-2023 | Exkivity |
| Helsinn Therapeutics (U.S.), INC. | $1,800.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $1,439.28 | 2020-2023 | Rezlidhia, Tavalisse |
| Kite Pharma, INC. | $1,429.19 | 2020-2025 | Yescarta |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,229.45 | 2022-2025 | Enhertu, Vanflyta |
| Genzyme Corporation | $1,199.70 | 2021-2024 | |
| Aveo Pharmaceuticals, INC. | $1,065.07 | 2021-2022 | |
| Cti Biopharma Corp. | $1,018.28 | 2022-2023 | Vonjo |
| Partner Therapeutics, INC. | $1,000.00 | 2025 | Bizengri |
| Beigene, LTD. | $975.00 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $961.72 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $889.79 | 2020-2025 | Clonoseq |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $728.37 | 2019-2023 | |
| Astellas Pharma US INC | $586.47 | 2021-2024 | Xtandi |
| Emd Serono, INC. | $526.15 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $469.21 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $436.20 | 2020-2023 | Verzenio, Jaypirca |
| Puma Biotechnology, INC. | $427.19 | 2020-2025 | |
| Incyte Corporation | $319.54 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $273.24 | 2022-2024 | Opdivo, Pomalyst |
| Abbvie INC. | $167.90 | 2023-2025 | Venclexta |
| Tempus Ai, INC | $162.67 | 2024 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2020 | |
| Foundation Medicine, INC. | $146.55 | 2023 | |
| Pharmacosmos Therapeutics INC. | $144.02 | 2023-2024 | Monoferric |
| Taiho Oncology, INC. | $141.47 | 2021-2022 | |
| Caris Mpi, INC. | $135.39 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $123.12 | 2021 | |
| Verastem, INC. | $116.96 | 2019 | |
| Merck Sharp & Dohme LLC | $116.28 | 2023-2025 | Keytruda, Welireg |
| Epizyme, INC. | $96.49 | 2022 | |
| Clovis Oncology, INC. | $95.00 | 2019 | |
| Amgen INC. | $86.19 | 2019 | |
| Axonics, INC. | $81.55 | 2024 | Axonics |
| Adc Therapeutics America, INC. | $74.58 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $72.87 | 2023-2025 | Libtayo |
| Eisai INC. | $69.14 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $56.57 | 2023-2024 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.48 | 2023-2025 | Gilotrif |
| Acrotech Biopharma INC. | $45.53 | 2021-2024 | Beleodaq |
| Stemline Therapeutics INC. | $41.20 | 2023-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $36.21 | 2019-2023 | Tazverik |
| Array Biopharma INC | $35.44 | 2025 | Braftovi, Lorbrena, Mektovi |
| Sobi, INC | $34.11 | 2022-2025 | |
| Pharmaessentia USA Corporation | $33.65 | 2022 | |
| Beone Medicines USA, INC. | $30.51 | 2025 | Tevimbra |
| Immunogen, INC. | $27.48 | 2023 | Elahere |
| Sun Pharmaceutical Industries INC. | $22.93 | 2023 | Yonsa, Odomzo |
| Servier Pharmaceuticals LLC | $22.76 | 2025 | |
| Secura Bio, INC. | $19.72 | 2020 | |
| Genentech USA, INC. | $18.83 | 2024 | Polivy |
| Syndax Pharmaceuticals, INC. | $17.05 | 2025 | |
| Kyowa Kirin, INC. | $14.99 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagathi Challagalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.